Trial Profile
A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Heart failure; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms HELP
- Sponsors Tenax Therapeutics
- 09 Apr 2024 According to a Tenax Therapeutics media release, presentation of review of data from the Phase 2 HELP Study by Barry Borlaug, M.D. (Mayo Clinic), will explore this most prevalent type of pulmonary hypertension and the therapeutic potential of levosimendan.
- 30 Mar 2022 According to a Tenax Therapeutics media release, data from the trial will be presented by Dr. Borlaug at the upcoming American College of Cardiology (ACC) Scientific Sessions 2022.
- 17 Aug 2021 According to a Tenax Therapeutics media release, results from this trial presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting